Healthy
Conditions
Brief summary
To investigate the relative bioavailability of telmisartan respectively of dipyridamole after concomitant administration of 80 mg telmisartan in Micardis® and 25 mg acetylsalicylic acid (ASA)/200 mg extended release (ER) dipyridamole (DP) in Aggrenox® (Test 1) relative to ER-DP in Aggrenox® alone (Reference 1), respectively relative to telmisartan in Micardis® alone (Reference 2). To investigate the relative bioavailability of dipyridamole respectively of telmisartan administered as 25 mg ASA/200 mg ER-DP 30 minutes after intake of 80 mg telmisartan (Test 2) relative to dipyridamole in Aggrenox® alone (Reference 1), respectively relative to telmisartan in Micardis® alone (Reference 2).
Interventions
DRUGtelmisartan
DRUGASA/ER-DP
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy females and males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (BP, HR), 12-lead ECG, clinical laboratory tests * No finding deviating from normal and of clinical relevance * No evidence of a clinically relevant concomitant disease 2. Age ≥21 and Age ≤65 years 3. BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index) 4. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation
Exclusion criteria
1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders 2. Surgery of gastrointestinal tract (except appendectomy) 3. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders 4. History of relevant orthostatic hypotension, fainting spells or blackouts. 5. Chronic or relevant acute infections 6. History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator 7. Intake of drugs with a long half-life (\>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial 8. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial 9. Participation in another trial with an investigational drug within two months prior to administration or during the trial 10. Smoker (more than 10 cigarettes/day or 3 cigars/day or 3 pipes/day) 11. Inability to refrain from smoking on trial days 12. Alcohol abuse (more than 60 g/day) 13. Drug abuse 14. Blood donation (more than 100 mL within four weeks prior to administration or during the trial) 15. Excessive physical activities (within one week prior to administration or during the trial) 16. Any laboratory value outside the reference range that is of clinical relevance 17. Inability to comply with dietary regimen of study centre 18. History of hereditary fructose intolerance 19. History of any familial bleeding disorder 20. Veins unsuited for i.v. puncture on either arm (e.g. veins which are difficult to locate, access or puncture, veins with a tendency to rupture during or after puncture, etc.) 21. Inability to comply with the investigators instructions For female subjects: 22. Pregnancy 23. Positive pregnancy test 24. No adequate contraception e.g. oral contraceptives, sterilization, intrauterine device (IUD) 25. Inability to maintain this adequate contraception during the whole study period 26. Lactation period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUC0-∞ (area under the concentration time curve in plasma from 0 extrapolated to infinity) | up to 72 hours following drug administration |
| Cmax (maximum concentration in plasma) | up to 72 hours following drug administration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AUCt1-t2 (Area under the concentration time curve in plasma over the time interval t1 to t2) | up to 72 hours following drug administration | — |
| tmax (time from dosing to the maximum concentration of the analytes in plasma) | up to 72 hours following drug administration | — |
| t1/2 (terminal half-life of the analytes in plasma) | up to 72 hours following drug administration | — |
| MRTpo (mean residence time of the analyte in the body after p.o. administration) | up to 72 hours following drug administration | — |
| CL/F (apparent clearance of the analytes in the plasma after extravascular administration) | up to 72 hours following drug administration | — |
| λz (terminal rate constant in plasma) | up to 72 hours following drug administration | — |
| Number of subjects with adverse events | up to 8 days after last drug administration | — |
| Number of subjects with clinically significant findings in vital signs | up to 8 days after last drug administration | blood pressure, heart rate |
| Number of subjects with clinically significant findings in 12 lead ECG | up to 8 days after last drug administration | — |
| Number of subjects with clinically significant findings in laboratory tests | up to 8 days after last drug administration | — |
| Assessment of tolerability by the investigator on a 4-point scale | up to 8 days after last drug administration | — |
| Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose) | up to 72 hours following drug administration | — |
| AUC0-tz (area under the concentration-time curve in plasma over the time interval from 0 to the time of the last quantifiable data point) | up to 72 hours following drug administration | — |
Outcome results
None listed